Radiotherapy — Cost, Top Hospitals & Success Rates | MyMedicPlus

<p>Radiotherapy (also called radiation therapy or radiation oncology) is the use of precisely controlled high-energy ionising radiation to damage the DNA of cancer cells, preventing them from dividing and ultimately causing their death. It is one of the three pillars of oncological treatment alongside surgery and systemic therapy (chemotherapy, targeted agents, and immunotherapy), and is used in approximately 50–60% of all patients diagnosed with cancer at some point in their treatment pathway.</p><p>The biological mechanism relies on radiation inducing DNA double-strand breaks (DSBs) in rapidly dividing cells. While normal cells possess robust repair mechanisms and can recover from radiation injury during the intervals between treatment fractions (the basis of <strong>fractionation</strong>), cancer cells — which often have defective DNA repair pathways — accumulate lethal damage over the course of treatment. The ratio of cancer cell kill to normal tissue toxicity is called the <strong>therapeutic ratio</strong>, and all technological advances in radiotherapy aim to maximise this ratio.</p><p>The history of radiotherapy stretches back to 1895 when Wilhelm Röntgen discovered X-rays, followed almost immediately by the first reported therapeutic radiation applications. Marie Curie's isolation of radium in 1898 enabled brachytherapy. The development of linear accelerators (linacs) in the 1950s and 1960s replaced older cobalt-60 units with more powerful, precise photon beams. The digital era brought computed tomography (CT)–based 3-dimensional treatment planning in the 1980s, intensity-modulated radiotherapy (IMRT) in the 1990s, image-guided radiotherapy (IGRT) in the 2000s, and stereotactic radiosurgery/body radiotherapy (SRS/SBRT) delivering ablative doses with sub-millimetre precision in the 2010s. Today, proton beam therapy, MR-Linac (real-time MRI guidance during treatment delivery), and artificial intelligence–driven adaptive radiotherapy represent the cutting edge.</p><p>Radiation is measured in <strong>Gray (Gy)</strong> — the unit of absorbed dose (1 Gy = 1 joule of energy absorbed per kilogram of tissue). A typical curative course for breast cancer might deliver 40–50 Gy in 15–25 daily fractions over 3–5 weeks; stereotactic body radiotherapy for early lung cancer delivers 48–60 Gy in just 3–5 fractions over one week. The radiation oncologist designs each patient's treatment plan using complex computerised dose optimisation software to maximise tumour dose and minimise dose to organs at risk (OARs) such as the heart, spinal cord, lungs, and bowel.</p><p>Modern radiotherapy is not a single technology but a family of precision-delivery systems, each with specific strengths for different tumour types, locations, and patient circumstances. The choice of modality is made by a multidisciplinary team including radiation oncologists, medical physicists, dosimetrists, and radiographers, and is guided by national and international guidelines from bodies including ASTRO (American Society for Radiation Oncology), ESTRO (European Society for Radiotherapy and Oncology), and national cancer networks.</p>

<p>Radiotherapy plays a role — curative, adjuvant, neoadjuvant, or palliative — in the management of virtually every solid tumour and many haematological malignancies. Key indications by organ system are listed below.</p><p><strong>Breast Cancer:</strong> Adjuvant whole-breast radiotherapy after breast-conserving surgery (BCS) reduces local recurrence by 50–70% and improves overall survival. Post-mastectomy radiotherapy (PMRT) is indicated for node-positive or locally advanced disease. Regional nodal irradiation targets axillary, supraclavicular, and internal mammary nodes. Modern techniques (DIBH — deep inspiration breath hold) minimise cardiac dose.</p><p><strong>Prostate Cancer:</strong> Definitive external beam radiotherapy or brachytherapy achieves equivalent biochemical disease-free survival to radical prostatectomy for localised prostate cancer across risk groups. Stereotactic body radiotherapy (SBRT) delivers treatment in 5 fractions (ultra-hypofractionation), exploiting the favourable radiobiology of prostate cancer (low alpha/beta ratio). Combined with androgen deprivation therapy (ADT) for high-risk disease.</p><p><strong>Lung Cancer:</strong> SBRT/SABR is standard of care for early-stage (I–II) NSCLC in medically inoperable patients, achieving 3-year local control rates of 85–95%. For locally advanced (stage III) NSCLC, concurrent chemoradiotherapy followed by durvalumab (anti-PD-L1) immunotherapy is the current standard. Palliative thoracic RT and endobronchial brachytherapy manage haemoptysis and obstruction.</p><p><strong>Head and Neck Cancers:</strong> Radiotherapy — often with concurrent cisplatin-based chemotherapy — is the cornerstone of organ-preservation strategies for laryngeal, oropharyngeal, and nasopharyngeal cancers, avoiding laryngectomy or mandibulectomy. IMRT is the standard technique to spare the parotid glands (reducing xerostomia) and spinal cord.</p><p><strong>Brain Tumours:</strong> Whole-brain radiotherapy (WBRT) for multiple brain metastases; stereotactic radiosurgery (SRS — Gamma Knife, CyberKnife, or linac-based) for 1–10 discrete metastases ≤4 cm. Post-operative radiotherapy for glioblastoma (Stupp protocol: 60 Gy/30 fractions with concurrent and adjuvant temozolomide). Proton therapy for paediatric brain tumours to minimise neurocognitive late effects.</p><p><strong>Gynaecological Cancers:</strong> Definitive chemoradiotherapy with intracavitary brachytherapy boost is curative for cervical cancer stages IB–IVA with outcomes equivalent to surgery for early stages. Adjuvant vaginal brachytherapy for intermediate-risk endometrial cancer reduces vaginal vault recurrence.</p><p><strong>Rectal and Colorectal Cancer:</strong> Neoadjuvant chemoradiotherapy (long course: 50 Gy/25 fractions or short course: 25 Gy/5 fractions) downstages locally advanced rectal cancer before surgery and significantly reduces local recurrence rates from 25–30% to 5–10%.</p><p><strong>Haematological Malignancies:</strong> Involved-field or involved-site radiotherapy (IFRT/ISRT) for Hodgkin's lymphoma and certain non-Hodgkin's lymphomas as part of combined modality treatment. Total body irradiation (TBI) as conditioning for allogeneic stem cell transplantation.</p><p><strong>Palliative Indications:</strong> Single-fraction (8 Gy) or short-course (20 Gy/5 fractions) RT provides highly effective pain relief for bone metastases (70–80% response rate). Palliative RT also addresses superior vena cava obstruction, spinal cord compression, brain metastases, and haemostasis for bleeding tumours.</p>

<p>Eligibility for radiotherapy is determined by a radiation oncologist within a multidisciplinary tumour board, balancing the therapeutic benefit of radiation against its toxicity in the specific patient context. Key eligibility considerations include:</p><p><strong>Oncological Factors:</strong></p><ul><li><strong>Tumour histology and radiosensitivity:</strong> Lymphomas, seminomas, and small cell lung cancer are highly radiosensitive. Melanoma and sarcomas are traditionally considered radioresistant at conventional doses but respond to hypofractionated or SBRT regimens. Squamous cell carcinomas of the head and neck, cervix, and anal canal are particularly amenable to curative chemoradiotherapy.</li><li><strong>Stage and tumour volume:</strong> Radiotherapy with curative intent is most appropriate for loco-regionally confined disease. Widely metastatic disease usually calls for palliative-intent RT directed at specific symptomatic sites.</li><li><strong>Prior irradiation history:</strong> Cumulative dose to organs at risk from previous courses limits re-irradiation options, though modern stereotactic re-irradiation techniques have expanded the possibilities. A detailed treatment history and dosimetric analysis of the prior plan are essential.</li><li><strong>Proximity to critical structures:</strong> Tumours immediately adjacent to the spinal cord, optic nerves, brainstem, bowel, or kidneys require highly conformal delivery (IMRT, proton therapy) to maintain safe dose constraints to these organs at risk.</li></ul><p><strong>Patient Factors:</strong></p><ul><li><strong>Performance status:</strong> ECOG 0–2 is generally required for curative-intent radiotherapy; ECOG 3–4 patients may still benefit from abbreviated palliative courses.</li><li><strong>Ability to maintain treatment position:</strong> Patients must lie still in the reproducible treatment position for 10–45 minutes per session. Severe pain, claustrophobia, or movement disorders may require management strategies (pain control, anxiolytics, general anaesthesia for children).</li><li><strong>Pre-existing conditions affecting radiosensitivity:</strong> Connective tissue disorders (scleroderma, SLE, rheumatoid arthritis) and certain genetic syndromes (ataxia-telangiectasia, Fanconi anaemia, Li-Fraumeni syndrome, BRCA2 homozygous mutations) are associated with enhanced normal tissue radiosensitivity and may be relative contraindications to radiotherapy.</li><li><strong>Pregnancy:</strong> Absolute contraindication in the first and second trimesters; may be considered in the third trimester for sites remote from the foetus with careful shielding. Treatment is generally deferred post-partum when possible.</li><li><strong>Implanted devices:</strong> Cardiac pacemakers and implantable cardioverter-defibrillators (ICDs) can be damaged by scatter radiation; electrophysiology input is required and device repositioning or close monitoring protocols must be in place.</li></ul><p><strong>Social Factors:</strong> Daily attendance at a radiotherapy centre for 3–7 weeks (for conventional fractionation) requires geographic access, transport, and ability to attend reliably. Hypofractionation (fewer, larger daily doses) and ultra-hypofractionation (SBRT) address access barriers by condensing treatment into 5–20 sessions.</p>

<p>Modern radiotherapy encompasses a broad spectrum of delivery technologies, each with distinct physical properties, clinical applications, and resource requirements.</p><p><strong>External Beam Radiotherapy (EBRT):</strong> The most widely used form, in which radiation is produced by a linear accelerator (linac) outside the body and directed through the skin to the tumour. Key technique variants include:</p><ul><li><strong>3D Conformal Radiotherapy (3D-CRT):</strong> Multiple fixed beams shaped to the tumour's three-dimensional contour using multileaf collimators (MLCs). The historical standard now largely supplanted by IMRT for complex treatments.</li><li><strong>Intensity-Modulated Radiotherapy (IMRT):</strong> Computer-optimised modulation of beam intensity across multiple angles, creating highly concave or heterogeneous dose distributions that spare adjacent critical structures while maintaining tumour dose. The current standard for head-and-neck, prostate, and intracranial tumours.</li><li><strong>Volumetric Modulated Arc Therapy (VMAT):</strong> A form of IMRT delivered as the gantry rotates continuously in one or two arcs, reducing treatment delivery time to 2–4 minutes versus 15–20 minutes for step-and-shoot IMRT.</li><li><strong>Image-Guided Radiotherapy (IGRT):</strong> Daily on-board imaging (kV X-ray, cone-beam CT, or MRI) verifies patient positioning and tumour location before each fraction, enabling tighter planning margins and greater tumour dose while reducing normal tissue exposure.</li><li><strong>Stereotactic Radiosurgery (SRS) and SBRT:</strong> Delivery of ablative radiation doses (typically 12–24 Gy per fraction) in 1–5 sessions to precisely defined targets using submillimetre accuracy frames or fiducial-based tracking. SRS targets intracranial lesions using Gamma Knife, CyberKnife, or linac. SBRT (also called SABR — stereotactic ablative radiotherapy) targets extracranial sites including lung, liver, spine, adrenal, and prostate.</li></ul><p><strong>Brachytherapy:</strong> Placement of radioactive sources directly within or immediately adjacent to the tumour, enabling very high local doses with rapid dose fall-off in surrounding tissues. Delivery methods include:</p><ul><li><strong>Intracavitary brachytherapy:</strong> Applicators placed in body cavities — uterine tandem and ovoid for cervical cancer, rectal applicator for rectal cancer</li><li><strong>Interstitial brachytherapy:</strong> Needles or seeds implanted directly into tissue — prostate seed implantation (LDR brachytherapy), breast interstitial brachytherapy</li><li><strong>High-dose rate (HDR) vs Low-dose rate (LDR):</strong> HDR uses a single high-activity source (iridium-192) robotically driven through applicators; LDR involves permanent or temporary seed implants (iodine-125, palladium-103)</li></ul><p><strong>Proton Beam Therapy:</strong> Protons deposit the majority of their energy at a specific depth (the Bragg peak) and then stop, delivering minimal exit dose beyond the target. This physical advantage is particularly valuable for paediatric tumours (minimising long-term developmental effects), base-of-skull chordomas and chondrosarcomas, and ocular melanomas. Proton centres remain limited globally and are significantly more expensive than photon therapy.</p><p><strong>MR-Linac:</strong> A revolutionary hybrid system combining a magnetic resonance imaging (MRI) unit with a linear accelerator, enabling real-time soft-tissue tumour visualisation during beam delivery. This allows online adaptive radiotherapy — the treatment plan is modified daily based on the observed tumour position and organ-at-risk anatomy — substantially improving dose conformality for mobile targets such as pancreatic, prostate, and liver tumours.</p><p><strong>Radionuclide Therapy:</strong> Systemic administration of radioactive isotopes targeting specific tumour molecules. Iodine-131 for differentiated thyroid cancer, Ra-223 (Xofigo) for bone-metastatic castration-resistant prostate cancer, Lu-177 DOTATATE (Lutathera) for somatostatin receptor–positive neuroendocrine tumours, and Lu-177 PSMA-617 for PSMA-positive prostate cancer represent current clinical standards in this rapidly expanding field.</p>

<p>Radiotherapy offers a unique and indispensable set of clinical advantages that make it a cornerstone of cancer care across virtually all tumour types and stages.</p><p><strong>Curative Potential Without Surgery:</strong> For many cancers — including early laryngeal cancer, anal canal cancer, cervical cancer, Hodgkin's lymphoma, and certain head-and-neck cancers — radiotherapy alone or combined with chemotherapy achieves cure rates equivalent to or exceeding surgery, while preserving the organ and its function. Larynx-preservation rates exceeding 80% in stage III–IV laryngeal cancer with definitive chemoradiotherapy represent one of oncology's most impactful organ-preservation achievements.</p><p><strong>Local Control After Surgery:</strong> Adjuvant (post-operative) radiotherapy dramatically reduces local recurrence in many cancer types. In breast cancer, adjuvant whole-breast RT after BCS reduces the 10-year local recurrence risk from approximately 30% to 10%, with a proportional improvement in breast cancer–specific survival. In rectal cancer, neoadjuvant chemoradiotherapy reduces local recurrence from 25% to less than 5%.</p><p><strong>Highly Effective Palliative Therapy:</strong> Even a single fraction of radiation (8 Gy) achieves clinically meaningful pain relief in 70–80% of patients with painful bone metastases, often within days, with complete pain response in 15–30%. For spinal cord compression, emergency RT can halt or reverse neurological deterioration. For brain metastases, SRS achieves local control rates of 85–90% at 1 year per treated lesion with low toxicity compared with whole-brain RT.</p><p><strong>Outpatient Treatment:</strong> Unlike major surgery, radiotherapy is delivered entirely on an outpatient basis. Patients arrive for their daily or weekly sessions, undergo a 10–30 minute treatment, and return home. For hypofractionated and stereotactic regimens, the entire treatment course is completed in 1–5 weeks rather than the traditional 6–7 weeks.</p><p><strong>Radiosensitising Synergy with Systemic Therapy:</strong> Chemotherapy agents (cisplatin, 5-FU, capecitabine, gemcitabine) and targeted agents (cetuximab) act as radiosensitisers, potentiating radiation cytotoxicity in tumour cells. Immunotherapy (anti-PD-1/PD-L1 checkpoint inhibitors) combined with RT creates an abscopal effect — local radiation can trigger systemic immune responses against metastatic lesions beyond the radiation field — a phenomenon being actively exploited in clinical trials.</p><p><strong>No Blood Loss or General Anaesthesia:</strong> Radiotherapy is entirely non-invasive. Patients with significant cardiovascular disease, coagulopathy, or poor anaesthetic risk who cannot undergo surgery can safely receive radiotherapy, making it the preferred modality for elderly or frail patients with early-stage cancers.</p><p><strong>Technological Precision:</strong> Modern IMRT, VMAT, IGRT, and SBRT deliver submillimetre positional accuracy with dose distributions sculpted to spare critical normal structures. MR-Linac adaptive radiotherapy adjusts the plan in real time to daily anatomical variations, further reducing normal tissue toxicity.</p>

<p>Radiotherapy side effects arise from unavoidable irradiation of normal tissues adjacent to the tumour. They are divided into acute effects (occurring during treatment and within 90 days) and late effects (developing months to years after treatment). Side effects are site-specific, dose-dependent, and influenced by the volume of tissue irradiated, fraction size, concurrent medications, and individual patient radiosensitivity.</p><p><strong>General Acute Side Effects (Applicable to Most RT Sites):</strong></p><ul><li><strong>Fatigue:</strong> The most universal side effect, affecting 70–90% of patients, typically beginning 2–3 weeks into treatment and peaking 1–2 weeks after completion. Often multifactorial (anaemia, sleep disruption, tumour-related cytokine release, treatment-related systemic inflammatory responses). Usually resolves within 6–12 weeks of completing treatment.</li><li><strong>Skin reactions (radiodermatitis):</strong> Ranging from mild erythema (redness, similar to sunburn) and desquamation (dry skin peeling) to moist desquamation in skin folds; managed with aqueous creams, barrier dressings, and topical hydrocortisone.</li><li><strong>Hair loss:</strong> Limited to the irradiated field; scalp hair loss is permanent above 40 Gy but usually regrows after lower doses.</li></ul><p><strong>Site-Specific Acute Effects:</strong></p><ul><li><strong>Head and neck RT:</strong> Oral mucositis (painful mouth sores), dysphagia, xerostomia (dry mouth), odynophagia, altered taste, weight loss requiring nasogastric or PEG feeding in severe cases</li><li><strong>Thoracic RT (lung/breast):</strong> Oesophagitis (heartburn, dysphagia), acute pneumonitis (cough, dyspnoea) in 5–10% at doses exceeding 20 Gy mean lung dose</li><li><strong>Abdominal/pelvic RT:</strong> Nausea, diarrhoea, urinary frequency, dysuria, pelvic pain; acute proctitis in rectal or prostate RT</li><li><strong>Brain RT:</strong> Cerebral oedema (headache, nausea) managed with corticosteroids; acute cognitive effects in whole-brain RT</li></ul><p><strong>Late Effects (Months to Years after Treatment):</strong></p><ul><li><strong>Fibrosis:</strong> Pulmonary fibrosis (persistent cough, dyspnoea after thoracic RT), subcutaneous fibrosis and skin tightening after breast RT, pelvic fibrosis affecting bowel, bladder, and sexual function after gynaecological or prostate RT</li><li><strong>Xerostomia (dry mouth):</strong> Chronic salivary gland dysfunction after head-and-neck RT, significantly improved by parotid-sparing IMRT but not completely eliminated</li><li><strong>Cardiovascular effects:</strong> Coronary artery disease, pericarditis, and valvular disease with long latency (10–20 years) after chest wall or mediastinal irradiation; modern cardiac-sparing techniques have substantially reduced this risk</li><li><strong>Secondary malignancy:</strong> A small but real risk (estimated 0.5–1% at 10 years); most relevant in long-term cancer survivors, particularly those treated in childhood or adolescence, in whom the absolute risk must always be weighed against the substantial survival benefit of radiation</li><li><strong>Neurocognitive effects:</strong> Whole-brain RT carries a 50–60% risk of clinically significant cognitive decline at 3–6 months; hippocampal-avoidance WBRT and memantine prophylaxis reduce this risk; SRS for limited metastases is preferred when feasible</li></ul><p>All patients should be counselled using standardised toxicity scales (Common Terminology Criteria for Adverse Events, CTCAE) and have access to specialist supportive care teams including dietitians, speech and language therapists, pelvic floor physiotherapists, and psycho-oncologists throughout and after treatment.</p>

<p>Structured post-radiotherapy surveillance serves several overlapping goals: monitoring treatment response, detecting disease recurrence at the earliest opportunity, managing acute and chronic toxicities, and addressing psychosocial and functional rehabilitation needs.</p><p><strong>Immediate Post-Treatment Period (Weeks 1–4):</strong></p><ul><li>The final radiotherapy fraction is followed by a scheduled clinical review at 4–6 weeks, allowing time for acute mucositis, oesophagitis, or skin reactions to begin resolving before assessment</li><li>Blood counts (if concurrent chemotherapy was delivered), renal function, and tumour marker assessment where applicable</li><li>Wound healing review for brachytherapy applicator insertion sites</li><li>Dietary and swallowing support for head-and-neck and oesophageal RT patients</li><li>Instructions for skin care: gentle washing, moisturising, avoidance of sun exposure to the irradiated field for 12 months</li></ul><p><strong>Tumour Response Assessment (8–12 Weeks Post-RT):</strong></p><ul><li>Cross-sectional imaging (CT, MRI, or PET-CT depending on tumour type) to assess treatment response using RECIST 1.1 criteria or PERCIST criteria (PET response)</li><li>Radiation-induced changes on imaging can be difficult to distinguish from residual tumour — particularly in lung (radiation pneumonitis mimicking residual disease) and brain (pseudoprogression) — and require expertise in post-RT imaging interpretation</li><li>PSA measurement at 3–6 months and every 6 months thereafter for prostate cancer; nadir PSA predicts long-term biochemical control</li><li>HPV oropharyngeal cancer: FDG-PET/CT at 12 weeks to confirm complete metabolic response and guide decision on neck dissection</li></ul><p><strong>Long-Term Surveillance and Late Effect Management:</strong></p><ul><li>Standardised tumour-type specific follow-up: mammography for breast cancer, endoscopy for oesophageal cancer, flexible sigmoidoscopy or colonoscopy for rectal cancer, cystoscopy for bladder cancer</li><li>Annual thyroid function testing for neck-irradiated patients (radiation-induced hypothyroidism in 20–40%)</li><li>Cardiac risk factor management and ECG/echo surveillance for patients who received significant mediastinal or breast irradiation</li><li>Bone density (DEXA) scanning for pelvic RT patients (radiation-induced ovarian failure or androgen deprivation) with osteoporosis prevention</li><li>Pelvic floor physiotherapy and vaginal dilator use to prevent stenosis after gynaecological brachytherapy</li><li>Neuropsychological assessment and cognitive rehabilitation for patients treated with brain RT, especially children</li></ul><p>Most radiation oncology departments operate a dedicated late-effects or survivorship clinic providing long-term holistic follow-up. All post-RT patients should report new symptoms — especially dyspnoea, haemoptysis, rectal bleeding, haematuria, neurological changes, or bone pain — promptly, as these may represent early signs of radiation toxicity or disease recurrence requiring urgent evaluation.</p>

<p>The cost of a radiotherapy course is influenced by the technology platform, number of fractions, anatomical site complexity, use of concurrent systemic agents, and country of treatment. Radiotherapy represents a capital- and resource-intensive treatment modality, though its value in cancer control is well-established through multiple health-economic analyses.</p><p><strong>Key Cost Drivers:</strong></p><ul><li><strong>Treatment technique:</strong> Simple palliative RT (single or five fractions with basic planning) is the lowest-cost option. IMRT/VMAT with CT simulation, dosimetry, and image guidance is intermediate. SBRT with respiratory gating and 4D-CT planning is more expensive. Proton beam therapy is the most expensive, with single-course costs 2–3 times higher than equivalent photon IMRT.</li><li><strong>Number of fractions:</strong> A 30-fraction IMRT course (daily for 6 weeks) costs significantly more than a 5-fraction SBRT course delivering equivalent biological dose. The global trend toward hypofractionation is partly driven by cost-efficiency as well as patient convenience.</li><li><strong>Concurrent systemic therapy:</strong> Adding weekly cisplatin, 5-FU infusion, or cetuximab to RT substantially increases total treatment cost through chemotherapy drug acquisition, administration, and toxicity management.</li><li><strong>Brachytherapy:</strong> High-dose rate (HDR) brachytherapy applicators, afterloader systems, and operating theatre time add cost; however, fewer outpatient fractions may offset this.</li><li><strong>Treatment planning complexity:</strong> Adaptive planning, 4D motion management, biological optimisation, and quality assurance physics time add $500–3,000 to complex treatment plans.</li><li><strong>Supportive care:</strong> Nutritional support, anti-emetics, mucositis management, growth factors for concurrent chemoradiotherapy, and psychological support contribute to total episode costs.</li></ul><p><strong>Indicative Cost Ranges by Country (USD, full course):</strong></p><ul><li><strong>USA:</strong> Conventional EBRT $15,000–$50,000; IMRT/VMAT $25,000–$65,000; SBRT $20,000–$45,000; Proton therapy $40,000–$120,000</li><li><strong>United Kingdom (private):</strong> IMRT £10,000–£25,000; SBRT £12,000–£30,000</li><li><strong>India:</strong> IMRT/VMAT $2,500–$7,000; SBRT $3,000–$10,000; Proton therapy $15,000–$30,000</li><li><strong>Thailand:</strong> IMRT $5,000–$15,000; SBRT $6,000–$18,000</li><li><strong>Turkey:</strong> IMRT $4,000–$12,000; SBRT $5,000–$15,000</li></ul><p>In countries with universal healthcare (UK NHS, European national health systems, Canada, Australia), radiotherapy for cancer is fully funded without patient cost. In the USA, Medicare and Medicaid cover medically necessary RT; private insurance coverage varies by policy. Medical travel to JCI- or NABH-accredited centres in India, Thailand, or Turkey can deliver equivalent technological quality (including IMRT, VMAT, SBRT, and even proton therapy) at 70–80% cost reduction for international patients.</p>

<p>The choice between radiotherapy and its alternatives depends on tumour type, stage, patient performance status, prior treatment history, and patient preferences. Alternatives are not mutually exclusive — multimodality strategies combining radiotherapy with surgery or systemic therapy frequently produce superior outcomes to any single modality alone.</p><p><strong>Surgery:</strong> For many solid tumours — breast, lung, colon, prostate, renal, gastric, and pancreatic cancers — surgery provides definitive local control through complete resection with clear margins. Surgery is preferred when the tumour is readily resectable, the patient can tolerate general anaesthesia, and organ function permits. RT may be used after surgery (adjuvant) to sterilise microscopic residual disease. For some cancers (early laryngeal, anal canal, cervical) RT avoids surgery entirely, preserving organ function.</p><p><strong>Systemic Chemotherapy:</strong> Used as the primary modality for haematological malignancies (leukaemia, most lymphomas) and disseminated solid tumours. Chemotherapy targets cancer cells throughout the body but cannot deliver concentrated local control equivalent to RT or surgery in localised disease. In locally advanced cancers, concurrent chemoradiotherapy exploits complementary mechanisms and is superior to either modality alone.</p><p><strong>Targeted Therapy and Immunotherapy:</strong> Molecularly targeted agents (EGFR inhibitors, ALK inhibitors for lung cancer; HER2-directed therapy for breast cancer; BRAF/MEK inhibitors for melanoma) and immune checkpoint inhibitors (anti-PD-1/PD-L1 antibodies) have transformed systemic cancer treatment and can sometimes defer or replace radiotherapy in specific genomically defined patient subgroups. Immunotherapy combined with RT is an area of active research with promising abscopal effect data.</p><p><strong>Ablative Procedures:</strong> For liver, lung, renal, and bone tumours that could be managed with either SBRT or percutaneous ablation (RFA, microwave ablation, cryoablation), the choice depends on tumour size, location, patient anticoagulation status, and centre expertise. SBRT does not require sedation or needle insertion and is preferred for central or vascular lesions; ablation may be preferred for peripheral lesions where a single treatment is possible.</p><p><strong>Active Surveillance:</strong> For very-low-risk prostate cancer (PSA ≤10, Gleason 6, T1c–T2a, fewer than 3 positive biopsy cores) and low-risk thyroid microcarcinoma, active surveillance with regular PSA or ultrasound monitoring defers radiotherapy or surgery indefinitely in many patients without compromising long-term cancer-specific survival. The decision requires careful informed discussion about monitoring intensity and the psychological burden of living with untreated cancer.</p><p><strong>Hormone Therapy:</strong> Androgen deprivation therapy (ADT) for prostate cancer, and anti-oestrogen therapy (tamoxifen, aromatase inhibitors) for certain breast cancers can serve as primary systemic treatments in specific contexts. ADT combined with radiotherapy enhances the efficacy of RT in intermediate- and high-risk prostate cancer.</p><p><strong>Watchful Waiting / Best Supportive Care:</strong> For elderly or frail patients with limited life expectancy or slowly progressive cancers, where treatment toxicity may outweigh the survival benefit, watchful waiting with symptom-directed palliative care may be the most appropriate approach. This decision should always be made collaboratively with the patient and their family after full discussion of goals of care.</p>